We are a biotechnology company dedicated to developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. We focus on products that address signaling pathways that are critical to disease mechanisms.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Grifols (exclusive commercialization license, Europe/UK/Turkey/Middle East/North Africa/Russia-CIS); Kissei (exclusive license and supply, approved in Korea Jan 2025); Medison (Canada and Israel, chronic ITP); Knight Therapeutics International (Latin America)
Indications
chronic immune thrombocytopenia (ITP)(Approved)
Status note First FDA-approved product; only approved oral SYK inhibitor for adult chronic ITP patients with insufficient response to prior treatment. Commercialized ex-US through multiple licensees.
olutasidenib
Phase 2 · ActiveModality: oral small molecule (IDH1 inhibitor)
Target IDH1
Partnerships MD Anderson Cancer Center and CONNECT (development collaborations for IDH1-mutation disease areas); Kissei (exclusive development/commercialization rights in Kissei territory, Sept 2024)
Indications
relapsed or refractory acute myeloid leukemia (AML) with IDH1 mutation(Approved)
glioma(Phase 2)
Status note Second FDA-approved product (REZLIDHIA) for adult R/R AML with susceptible IDH1 mutation. In Jan 2024 Rigel announced a collaboration with CONNECT to evaluate olutasidenib in glioma via the molecularly guided Phase 2 umbrella TarGet study (first patient enrolled Oct 2025).
R289
Phase 1 · ActiveModality: small molecule inhibitor
Status note Dual IRAK1/4 inhibitor in open-label Phase 1b study evaluating safety, tolerability and preliminary efficacy in patients with lower-risk MDS relapsed, refractory or resistant to prior therapy.
Per-asset detail extracted from the 10-Q filed 2026-08-04. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (0 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.